Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
124.34
+2.98 (+2.46%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
69
70
Next >
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
Today 17:30 EST
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q3 Earnings?
January 05, 2026
Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 10.1%.
Via
StockStory
Topics
Stocks
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child
↗
January 05, 2026
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.
Via
Stocktwits
Topics
Government
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs
↗
December 22, 2025
Via
Stocktwits
3 Cash-Flow Machines Investors May Want Heading Into 2026
↗
January 02, 2026
Via
MarketBeat
Here's How Much $1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
↗
January 01, 2026
Via
Benzinga
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value
December 31, 2025
As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
What's Driving the Market Sentiment Around Gilead Sciences Inc?
↗
December 31, 2025
Via
Benzinga
Stock Index Futures Slip in Weak End to a Banner Year
December 31, 2025
March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of...
Via
Barchart.com
Topics
Bonds
Government
Stocks
Discover which S&P500 stocks are making waves on Tuesday.
↗
December 30, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
GILEAD SCIENCES INC (NASDAQ:GILD) Shows High Technical and Setup Ratings for a Potential Breakout
↗
December 27, 2025
Gilead Sciences (GILD) shows strong technicals and a high-quality setup, suggesting a potential breakout from a tight trading range for chart-focused investors.
Via
Chartmill
Jobless Claims Unexpectedly Fall For Second Consecutive Week
↗
December 24, 2025
According to data released by the U.S. Department of Labor on Wednesday, jobless claims fell by 10,000 to 214,000 in the week ended December 20.
Via
Stocktwits
Topics
Stocks
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million
↗
December 24, 2025
Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.
Via
Benzinga
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug
↗
December 24, 2025
Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.
Via
Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk
↗
December 23, 2025
Via
Stocktwits
Topics
Government
These S&P500 stocks are moving in today's session
↗
December 23, 2025
Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Via
Chartmill
Gilead Sciences to Present at Upcoming Investor Conference
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes
↗
December 22, 2025
Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.
Via
Benzinga
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
December 22, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
↗
December 20, 2025
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.
Via
Benzinga
Topics
Government
Why Gilead Sciences (GILD) Stock Is Up Today
December 19, 2025
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive...
Via
StockStory
Topics
Earnings
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants
↗
December 19, 2025
The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.
Via
Stocktwits
Topics
Government
World Trade
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
↗
December 19, 2025
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.
Via
Investor's Business Daily
Topics
Government
Stocks
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
December 19, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Inc. (NASDAQ:GILD): A High-Quality Dividend Stock for Reliable Income
↗
December 19, 2025
Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts.
Via
Chartmill
AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report
↗
December 19, 2025
This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.
Via
Stocktwits
Topics
Economy
Government
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
December 18, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks
↗
December 17, 2025
The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.
Via
Stocktwits
Topics
Government
World Trade
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
↗
December 17, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
69
70
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
